MedWatch

Analyst on Novo stock: The risk of disappointments is bigger than the chance of surprises

2021 has been a golden year for Novo Nordisk, says a Jyske Bank analyst, whose recommendation for Novo stock is "hold" because of noteworthy price increases.

Photo: Jyske Bank/PR

Danish bank Jyske Bank is raising its share price target for Novo Nordisk stock to DKK 780 (USD 117.6) from DKK 670 (USD 100.1), according to an analysis the bank has conducted.

In connection with this, the bank maintains its recommendation to "hold." The huge share price increase this year has meant that the bank cannot justify the recommendation "buy," despite the stock's upward momentum.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs